Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office relating to its new formulation of Acetadote® (acetylcysteine) Injection, which is used to treat acetaminophen poisoning. The new formulation was FDA approved in 2011 and listed in the “Orange Book,” the FDA’s official register of approved pharmaceutical products. Once issued, the patent will expire in August 2025.

This composition of matter patent represents another significant milestone for Cumberland and its Acetadote brand. The proprietary next generation formula does not contain Ethylene diamine tetracetic acid (EDTA) or any other stabilization and chelating agents and is free of preservatives. The formulation also has a longer shelf life of 30 months compared to 24 for the prior formulation. This new formulation was developed as part of a Phase IV commitment by Cumberland in response to a request by the FDA to remove EDTA. Following the approval of the next generation Acetadote product, the Company immediately ceased manufacture of the previous formulation.

Acetadote is used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter pain relief and fever-reducing products. Acetaminophen continues to be the leading cause of poisonings reported by hospital emergency rooms in the United States, and Acetadote has become a standard of care for treating this potentially life-threatening condition.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company’s primary target markets include hospital acute care and gastroenterology. Cumberland’s product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever available in the United States; and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients.

More about CPIX at www.cumberlandpharma.com.

*********************************************

Big Lots, Inc. (NYSE:BIG) is reporting retail sales for U.S. operations for the fourth fiscal quarter of 2011 ended January 28, 2012 of $1,622.9 million, an increase of 7.7% compared to $1,507.1 million for the fourth quarter of fiscal 2010. Comparable store sales, for stores open in the United States for at least two years at the beginning of the fiscal year, increased 3.4% for the fourth quarter of fiscal 2011. These results exceeded our guidance which called for a 1% to 2% increase in comparable store sales.
Big Lots, Inc., through its subsidiaries, operates as a broad line closeout retailer in the United States.

*********************************************

Simpson Manufacturing Co., Inc. (NYSE:SSD) announced its fourth quarter 2011 results. The following discussion refers only to continuing operations unless otherwise indicated. For the fourth quarter of 2011, net sales increased 9.3% to $130.7 million compared to net sales of $119.6 million for the fourth quarter of 2010. The Company had income, net of tax, of $4.9 million for the fourth quarter of 2011 compared to a loss, net of tax, of $4.5 million for the fourth quarter of 2010. Diluted income, net of tax, per common share was $0.10 for the fourth quarter of 2011 compared to diluted loss, net of tax, of $0.09 per common share for the fourth quarter of 2010.

Simpson Manufacturing Co., Inc., through its subsidiaries, engages in the design, engineering, manufacture, and sale of building products.

*********************************************

Parker Drilling Company (NYSE:PKD) announced it intends to report its financial results for the Fourth Quarter 2011 on Thursday, Feb. 23. The Company expects to issue its earnings report that morning and will follow with a conference call at 10:00 a.m. CST (11:00 a.m. EST). Those interested in listening to the call by telephone may do so by dialing (480) 629-9819. Alternatively, the call can be accessed through the Investor Relations section of the Company’s website at http://www.parkerdrilling.com. A copy of the earnings report and related information will be available on the Company’s website. A replay of the call can be accessed on the Company’s website for 12 months or by telephone from Feb. 23 through March 1 by dialing (303) 590-3030 and using the access code 4510634#.

Parker Drilling Company, together with its subsidiaries, provides contract drilling and drilling-related services in the United States, Latin America, Africa and the Middle East (AME), the Asia Pacific, and Commonwealth of Independent States (CIS).

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.